GO
Loading...

Cubist Pharmaceuticals Inc

More

  • Jan 5- Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Shares of Cempra, among a clutch of smaller companies developing treatments to fight super-bugs, rose as much as 18 percent to $27.10 in early trading on Monday. WBB Securities' Steve...

  • Jan 5- Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Data showed solithromycin actually outperformed moxifloxacin by a slight margin, Cempra said on Sunday. North Carolina- based Cempra is also evaluating an intravenous formulation of...

  • Dec 17- Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck& co Inc's ertapenem in a late-stage study. Tetraphase is also testing the drug against Johnson& Johnson's levofloxacin to treat complicated urinary tract infections in another late-stage study, the results of which are...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • NEW YORK/ WASHINGTON, Dec 11- U.S. prosecutors, already smarting from a appeals court ruling that weakens their ability to crack down on future insider trading, on Thursday faced widening fallout from the decision as some existing cases threatened to unravel. Lawyers for some defendants hinted they might seek to withdraw guilty pleas, and a Manhattan federal...

  • Cramer's personal connection to Merck acquisition Monday, 8 Dec 2014 | 6:48 PM ET
    A researcher works in a microbiology laboratory at the Cubist Pharmaceuticals research facility in Lexington, Massachusetts.

    Jim Cramer has a personal connection to why he approves of Merck's acquisition of Cubist. Find out why.

  • Trader on the floor of the New York Stock Exchange.

    Stocks declined Monday as trade numbers from China came in below expectations and oil companies were knocked by the falling price of crude.

  • Cubist options unusually active before Merck deal Monday, 8 Dec 2014 | 12:50 PM ET

    NEW YORK, Dec 8- Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck& Co will buy Cubist for a hefty premium. Merck said it will pay $102 a share for Cubist, 37 percent above the Lexington, Massachussetts, company's closing share price of $74.36 on Friday. Implied volatility jumped to...

  • NEW YORK, Dec 8- U.S. stocks were little changed on Monday, as investors weighed the strength of the U.S. economy against global growth concerns following soft data out of China and Japan, while biotechs rose on merger activity. Major indexes opened slightly lower after data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7...

  • NEW YORK, Dec 8- U.S. stocks dipped on Monday, after soft data in China and Japan raised global growth concerns, while a further drop in oil prices weighed on energy shares. Data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third quarter.

  • NEW YORK, Dec 8- U.S. stocks were poised for a lower open on Monday, putting the S&P 500 on track to pull back from its latest record high, as soft data in China and Japan kindled global growth concerns. Economic data showed China's exports rose at a slower than expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in...

  • NEW YORK, Dec 8- U.S. stock index futures dipped on Monday, indicating the S&P 500 may retreat from its latest record high, as soft data in China and Japan kindled global growth concerns. *Economic data showed China's exports rose at a slower than expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third...

  • Cubist Pharm's shares soar on BIG Merck deal Monday, 8 Dec 2014 | 7:59 AM ET
    A researcher at a Cubist Pharmaceuticals lab.

    Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.

  • Early movers: CBST, MRK, EBAY, SBUX, INFY & more Monday, 8 Dec 2014 | 7:52 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures fall after soft China, Japan data Monday, 8 Dec 2014 | 7:37 AM ET

    NEW YORK, Dec 8- U.S. stock index futures dipped on Monday, indicating the S&P 500 may retreat from a record high, as soft data in China and Japan stoked global growth concerns. *Merck& Co Inc said it would buy Cubist Pharmaceuticals Inc in a deal valued at $9.5 billion. *European shares were lower after the data from China and Japan.

  • Merck in talks to buy Cubist for over $8B Friday, 5 Dec 2014 | 11:51 PM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Drug giant Merck is in talks to acquire antibiotics maker Cubist for about $102 a share in cash, according to people familiar with the matter.

  • The R&D elite: America's most innovative companies Wednesday, 6 Aug 2014 | 6:00 AM ET

    The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.

  • Yellen's 'stretched valuations' remark no surprise Tuesday, 15 Jul 2014 | 11:43 AM ET
    Janet Yellen

    Fed Chair Janet Yellen highlights that some sectors, like social media and biotech, are seeing stretched valuations.

  • Cubist Pharma waging a war against superbugs Monday, 16 Dec 2013 | 12:49 PM ET
    A researcher works in a microbiology laboratory at the Cubist Pharmaceuticals research facility in Lexington, Mass.

    Cubist Pharmaceuticals is focused on treatments for fighting superbugs, an area many drug developers are avoiding. But its success may attract their attention.

  • Cubist Pharmaceutical CEO Michael Bonney talks to CNBC's Bertha Coombs about his company's big bet on antibiotics to treat superbugs, which recently drove the firm to acquire two smaller rivals. He leaves the door open to future deals.